ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Only 2 Ph-neg CML patients failed TKIs therapy; in one a secondary change occurred, confirming that BCR/ABL duplication remains a mechanism of resistance to the therapy, also in TKI era.